A Resource Guide to Investing in Biotechnology
Directory - Encyclopedia - Stock Index - Drugs  

Biotech100 Stock Index

Myogen Inc.

About Myogen

Myogen is a biopharmaceutical company focused on the discovery, development and commercialization of small molecule therapeutics for the treatment of cardiovascular disorders.

Myogen currently markets one product in Europe, Perfan I.V., for the treatment of acute decompensated heart failure, and they have three product candidates in late-stage clinical development: enoximone capsules for the treatment of chronic heart failure, ambrisentan for the treatment of pulmonary arterial hypertension and darusentan for the treatment of resistant systolic hypertension. Myogen, in partnership with Novartis, also conducts a target and drug discovery research program focused on the development of disease-modifying drugs for the treatment of chronic heart failure and related cardiovascular disorders.




Product Pipeline for Myogen



Perfan I.V.-- Acute Deompensated Heart Failure Marketed

Enoximone Capsules -- Advanced Chronic Heart Failure

Ambrisentan -- Pulmonary Arterial Hypertension

Darusentan -- Uncontrolled Hypertension



More on Myogen

Home Page

Key Statistics for Myogen

Basic Chart for Myogen

Analyst Opinion

Analysts Estimates


Biotech100 Index
What are the Requirements to be listed in the Biotech100 Index?
See the Biotech100 List

Sponsored Links

Clinical Trials
What is a Clinical Trial?
Phase I ,-- Phase II, -- PhaseIII
What is Randomized Control?
 What is a Double Blind Experiment?
What is the role of the FDA?


Key Biotech Terms


Biotech Resources


Investing in Stocks
Small Cap Stocks
Stocks and Bonds
Biotech100 Index

Careers and Employment
Biotechnology and Pharmaceutical
What are the Fastest Growing Careers?




Copyright 2005 BIOTECH100.COM. All rights reserved.